Cat. No.: HY-122678

LQZ-7F

Customer Review

Based on 1 Customer Validation

LQZ-7F, a survivin dimerization inhibitor, induces spontaneous apoptosis and synergizes with Docetaxel in prostate cancer cells. LQZ-7F dose-dependently inhibits survival of both PC-3 and C4-2 cells with IC₅₀s of 2.99 and 2.47 µM, respectively.

For research use only. We do not sell to patients.

Purity: 97.44%
CAS No.: 354543-09-2
Formula: C₁₄H₇N₉O₃
Molecular Weight:349.26

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

LQZ-7F Chemical Structure

CAS No.: 354543-09-2

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A549	EC₅₀	0.8 μM Compound: LQZ-7F	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay	[PMID: 33569941]
HCT-116	EC₅₀	1.6 μM Compound: LQZ-7F	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay	[PMID: 33569941]
HCT-116	IC₅₀	0.99 μM Compound: 18, ZINC02092166	Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTS assay	[PMID: 25985283]
HEK293	IC₅₀	0.86 μM Compound: 18, ZINC02092166	Inhibition of interaction of beta-catenin (unknown origin) transfected in Wnt-activated HEK293 cells/Tcf4 assessed as decrease in transactivation of canonical Wnt signaling by TOPflash luciferase reporter assay Inhibition of interaction of beta-catenin (unknown origin) transfected in Wnt-activated HEK293 cells/Tcf4 assessed as decrease in transactivation of canonical Wnt signaling by TOPflash luciferase reporter assay	[PMID: 25985283]
HL-60	EC₅₀	1.2 μM Compound: LQZ-7F	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay	[PMID: 33569941]
HT-29	IC₅₀	1.1 μM Compound: 18, ZINC02092166	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 72 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 72 hrs by MTS assay	[PMID: 25985283]
LNCaP C4-2	IC₅₀	1.9 μM Compound: 7; LQZ-7F	Antiproliferative activity against human LNCaP C4-2 cells assessed as cell growth inhibition Antiproliferative activity against human LNCaP C4-2 cells assessed as cell growth inhibition	[PMID: 38092421]
LNCaP C4-2	IC₅₀	1.9 μM Compound: 7; LQZ-7F	Cytotoxicity against human LNCaP C4-2 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Cytotoxicity against human LNCaP C4-2 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 38092421]
LNCaP C4-2	IC₅₀	2.47 μM Compound: 7F; LQZ-7F	Cytotoxicity against human LNCaP C4-2 cells assessed as reduction in cell viability incubated for 72 hrs by methylene blue survival assay Cytotoxicity against human LNCaP C4-2 cells assessed as reduction in cell viability incubated for 72 hrs by methylene blue survival assay	[PMID: 35504208]
PC-3	IC₅₀	1.3 μM Compound: 7; LQZ-7F	Anticancer activity against human PC-3 cells assessed as cell growth inhibition by sulforhodamine B assay Anticancer activity against human PC-3 cells assessed as cell growth inhibition by sulforhodamine B assay	[PMID: 38092421]
PC-3	IC₅₀	2.99 μM Compound: 7F; LQZ-7F	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by methylene blue survival assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by methylene blue survival assay	[PMID: 35504208]
PC-3	IC₅₀	4.3 μM Compound: 7; LQZ-7F	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38092421]
SW480	IC₅₀	0.71 μM Compound: 18, ZINC02092166	Inhibition of beta-catenin/Tcf4 interaction in human SW480 cells assessed as decrease in transactivation of canonical Wnt signaling by TOPflash luciferase reporter assay Inhibition of beta-catenin/Tcf4 interaction in human SW480 cells assessed as decrease in transactivation of canonical Wnt signaling by TOPflash luciferase reporter assay	[PMID: 25985283]
SW480	IC₅₀	0.85 μM Compound: 18, ZINC02092166	Cytotoxicity against human SW480 cells assessed as inhibition of cell growth after 72 hrs by MTS assay Cytotoxicity against human SW480 cells assessed as inhibition of cell growth after 72 hrs by MTS assay	[PMID: 25985283]

In Vitro

LQZ-7F could be hudrolyzed under acidic conditions^[1].
LQZ-7F (2.5 μM, 72 hours) displays cytotoxicity towards human cancer cells (PC-3, C4-2) with the IC₅₀s of 2.99 μM and 2.74 μM, respectively^[1].
LQZ-7F effectively inhibits survival of all cancer cell lines with IC₅₀ values ranging between 0.4 and 4.4 mM^[2].
LQZ-7F (2 μM, 24 hours) disrupts microtubule structure and cause mitotic arrest in P3 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

PC3, HL-60 cells
Concentration:

0, 5, 10 μM
Incubation Time:
Result:

Caused 54% to 69% apoptosis for PC3 and 66% to 98% apoptosis for HL-60 cells.

Cell Cytotoxicity Assay^[1]

Cell Line:

PC-3, DU145
Concentration:

10, 20 μM
Incubation Time:

72 hours
Result:

Showed that the IC₅₀ in human PC3 and DU145 cells was approximately 25 μM.

In Vivo

LQZ-7F (i.p. injection; 25 mg/kg once every 3 days; 24 days) inhibits growth of xenograft tumor and may be due to its induction of surviving degradation in vivo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

4- to 6-week-old male NSG (NOD/SCID/IL-2Rg null) mice^[2].
Dosage:

25 mg/kg
Administration:

24 days
Result:

Inhibited growth of xenograft tumors by inhibiting surviving.

Chemical Information

CAS No. 354543-09-2
Appearance Solid
Molecular Weight 349.26
Formula C₁₄H₇N₉O₃
Color Yellow to orange
SMILES

O=C(C1=NON=C1N)N/N=C2C3=C(C4=NC5=NON=C5N=C4\2)C=CC=C3
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 5 mg/mL (14.32 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8632 mL

14.3160 mL

28.6320 mL

5 mM

0.5726 mL

2.8632 mL

5.7264 mL

10 mM

0.2863 mL

1.4316 mL

2.8632 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 10 mg/mL (28.63 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Robert Peery, et al. A novel survivin dimerization inhibitor without a labile hydrazone linker induces spontaneous apoptosis and synergizes with docetaxel in prostate cancer cells. Bioorg Med Chem. 2022 Jul 1;65:116761. [Content Brief]

[2]. Qi Jing, et al. Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors. Cancer Research. 2016 Jan. 76(2):453-462.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8632 mL	14.3160 mL	28.6320 mL	71.5799 mL
	5 mM	0.5726 mL	2.8632 mL	5.7264 mL	14.3160 mL
	10 mM	0.2863 mL	1.4316 mL	2.8632 mL	7.1580 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

LQZ-7F

MCE Bioactive Compound Library

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

LQZ-7F Related Classifications

Cat. No.: HY-122678